This program is funded by an independent grant from Merck. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.

Join our global experts for this accredited CME course on Advanced Prostate Cancer. The course is presented by leading Urology & Oncology experts, integrating the latest clinical insights into monotherapy and combination treatments for advanced prostate cancer. Hone your skills in developing personalized treatment plans for a diverse range of patients and settings, while integrating a multidisciplinary approach.

Appraise and apply current clinical trial data to clinical practice

Our expert speakers will translate existing and emerging data from clinical trials on both monotherapy and combination therapy into practical treatment approaches for patients with advanced prostate cancer. This course is designed to equip physicians with the knowledge to integrate the latest research findings into effective patient care strategies, critically appraising the quality and relevance of clinical studies to ensure that treatment decisions are centered around reliable and applicable evidence.

Develop personalized treatment plans for diverse patients

Our experts will share how to integrate detailed patient information with data from clinical trials on prostate cancer monotherapies and combination therapies. They will provide a framework to guide treatment approaches that are tailored to the individual needs of each patient. Attendees will be trained to balance the potential risks and benefits of various therapy options, ensuring that the chosen approach aligns with patient preferences and clinical requirements. This comprehensive strategy is aimed at optimizing treatment outcomes by addressing the unique circumstances of each patient.

Integrate multidisciplinary approaches when developing management plans for patients Attendees will learn to engage and collaborate effectively with a diverse team of professionals, including radiologists, pathologists, palliative care clinicians, urologists, oncologists, and research professionals. This collaboration is crucial for guiding comprehensive treatment planning for advanced prostate cancer. The course will cover how to optimize the unique resources and strengths of different treatment settings to enhance the multidisciplinary care of patients. This approach aims to foster a cohesive and holistic treatment environment that leverages the expertise of various specialists to improve patient outcomes.

Who is this course for

This online education program has been designed solely for healthcare professionals in the USA. The course provides continuing education for:

✅ Urologists

✅ Radiation oncologists

✅ Medical oncologists

✅ Clinical oncologists

✅ Urologic oncologists

✅ Pathologists

✅ Genetic testing experts

✅ Nuclear medicine physicians

✅ Family Physicians

✅ Physicians

✅ Physician Assistants

✅ Nurse Practitioners

✅ Other Health Professionals

Faculty

Professor Shawn Dason

Professor Dason specializes in surgical treatments for a range of cancers, including those of the prostate, kidney, and bladder, employing advanced techniques such as robotic and laparoscopic surgery. His practice is deeply rooted in understanding patient needs, tailoring care plans to individual goals, and ensuring clarity in communication about disease and treatment paths. Beyond surgery, Professor Dason is an advocate for multidisciplinary care and considers alternative treatments when they offer better outcomes. As an assistant professor in the Department of Urology at The Ohio State University College of Medicine, he contributes significantly to the field through both teaching and research. Recognized for his contributions, particularly in bladder cancer genomics, Professor Dason has received national awards and has an extensive publication record. His work at The James signifies a commitment to excellence in patient care, education, and research at one of the country's foremost cancer centers.

Professor Dakim Gaines

Professor Dakim Gaines is an Assistant Professor of Radiation Oncology at the Vanderbilt-Ingram Cancer Center. He earned his M.D./Ph.D. from Rutgers University after studying molecular biology at St. Mary's College of Maryland. Dr. Gaines completed his residency at Vanderbilt University Medical Center, engaging in the ABR Holman Pathway to research immunologic responses in kidney cancer post-SBRT. He specializes in genitourinary cancers and palliative radiotherapy and has been honored with multiple awards, including the 2021 ECOG-ACRIN Minority Scholarship Award.

Dr Andrew Laccetti

Dr. Andrew Laccetti earned his M.D. from Albany Medical College and an M.S. in Healthcare Leadership from Union College, NY. His residency in internal medicine was at UT Southwestern, Dallas, where he was also chief resident. He further specialized in medical oncology at the University of Texas MD Anderson Cancer Center. Now an Assistant Attending Physician at Memorial Sloan Kettering Cancer Center's Genitourinary Oncology Service, Dr. Laccetti's research focuses on androgen receptor signalling inhibitors in prostate cancer, investigating their long-term toxicities, and exploring remote monitoring techniques for cancer patients using innovative healthcare technologies.

Jeremy Patch, Director of Patient Programs at ZERO Prostate Cancer

For more than 25 years, ZERO Prostate Cancer has helped people and families impacted by prostate cancer. Jeremy Patch, ZERO's Director of Patient Programs & Education, brings a wealth of experience from the nonprofit and public health sectors to his role. Based in St. Louis, he has a history of leadership in cancer-focused nonprofits, including a notable stint at Susan G. Komen. With a B.A. in Psychology from Truman State University and an MPH from Saint Louis University, Jeremy has dedicated himself to public health, focusing on grantmaking, community needs assessment, and educational initiatives in oncology. At ZERO, he is driven by the goal to support cancer patients and families, aiming to reduce the impact of prostate cancer.

Faculty, planners, and staff disclosure information

Current Concepts Institute/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.

Shawn Dason, Dakim Gaines & Jeremy Patch have no relevant financial or non-financial interests to disclose.​

Andrew Laccetti has research contracts with ESSA and Bayer. He has received research funding from Johnson & Johnson. He is on a steering committee for Bayer. He has provided consulting for Guidepoint & Musculo. He has Stock options in Musculo​

Unapproved and/or off-label use disclosure

Current Concepts Institute/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Accreditation statement

AMA PRA Category 1 Credits™ are available for this activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.

Current Concepts Institute designates this online activity a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

This continuing education activity is active starting June 5 2024 and will expire on June 5 2025. Estimated time to complete this activity: 1.25 hours.